Lebrikizumab in the personalized management of asthma
Neil C Thomson,1 Manish Patel,2 Andrew D Smith21Institute of Infection, Immunity, and Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK; 2Department of Respiratory Medicine, Wishaw Hospital, Wishaw, Lanarkshire, UKAbstract: There is a need for impr...
Guardado en:
Autores principales: | Thomson NC, Patel M, Smith AD |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cee825f901ba45e4abab67fd7204c126 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical utility of asthma biomarkers: from bench to bedside
por: Vijverberg SJH, et al.
Publicado: (2013) -
Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles
por: Wang W, et al.
Publicado: (2012) -
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
por: Walsh GM
Publicado: (2013) -
Attenuation of allergic airway inflammation and hyperresponsiveness in a murine model of asthma by silver nanoparticles
por: Hee Sun Park, et al.
Publicado: (2010) -
Association between Asthma in Children and Mode of Delivery
por: E Mohammadzadeh,, et al.
Publicado: (2009)